Reactive Arthritis: Treatment Challenges and Future Perspectives.


Journal

Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970

Informations de publication

Date de publication:
26 05 2020
Historique:
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 3 11 2021
Statut: epublish

Résumé

Reactive arthritis is synovitis related to an infection away from the joint. The evolution is variable, frequently self-limited, but with the possible evolution to a prolonged form, generating functional incapacity and sequelae. New microbiological families have been incriminated and pathophysiological links have been clarified, highlighting the role of the mucous membranes (gut in particular), specific cell populations, and the production of pro-inflammatory cytokines. First-line pharmacological treatment is based on NSAIDs. In case of failure, synthetic and more recently biological DMARDs are indicated. Only open data are available for biological DMARDs but suggest good efficacy and safety. Reactive arthritis has not disappeared. The diagnosis must be mentioned by the clinic and history to allow the rapid introduction of an appropriate treatment.

Identifiants

pubmed: 32458153
doi: 10.1007/s11926-020-00904-9
pii: 10.1007/s11926-020-00904-9
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Antirheumatic Agents 0
Cytokines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

29

Auteurs

Daniel Wendling (D)

Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France. dwendling@chu-besancon.fr.
EA 4266, EPILAB, Université de Franche-Comté, Rue Ambroise Paré, 25030, Besançon, France. dwendling@chu-besancon.fr.

Clément Prati (C)

Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.
EA 4266, PEPITE, Université de Franche-Comté,, Rue Ambroise Paré, 25030, Besançon, France.

Mickael Chouk (M)

Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.

Frank Verhoeven (F)

Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France.
EA 4266, PEPITE, Université de Franche-Comté,, Rue Ambroise Paré, 25030, Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH